These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8097551)

  • 21. Eosinophilic ascites: taxol-induced hypersensitivity?
    Kobayashi TK; Muramatsu M; Ueda M; Nishino T; Bamba M; Urabe M; Moritani S
    Cytopathology; 2004 Jun; 15(3):171-2. PubMed ID: 15165278
    [No Abstract]   [Full Text] [Related]  

  • 22. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
    Yamazaki S; Sekine I; Saijo N
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):605-15. PubMed ID: 9530372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice.
    Ahmad I; Masters GR; Schupsky JJ; Nguyen J; Ali S; Janoff AS; Mayhew E
    Oncol Res; 1999; 11(6):273-80. PubMed ID: 10691029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New treatment for ovarian cancer poses ecology dilemma.
    Crumbie A
    Nurs Times; 1994 Jun 15-21; 90(24):34-5. PubMed ID: 7913219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topotecan: new preparation. No proven benefit.
    Prescrire Int; 1998 Apr; 7(34):48-9. PubMed ID: 10183383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.
    Mayerhofer K; Kucera E; Zeisler H; Speiser P; Reinthaller A; Sevelda P
    Gynecol Oncol; 1997 Jan; 64(1):109-13. PubMed ID: 8995557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adverse effect of paclitaxel plus carboplatin combination therapy related to administration schedule in patients with ovarian cancer].
    Fuse K; Tanaka T; Kagaya H; Suzuki T; Kimura A
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1295-7. PubMed ID: 11579644
    [No Abstract]   [Full Text] [Related]  

  • 31. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
    Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
    Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma.
    Schrader C; Keussen C; Bewig B; von Freier A; Lins M
    Eur J Med Res; 2005 Nov; 10(11):498-501. PubMed ID: 16354605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transverse leukonychia secondary to paclitaxel-carboplatin chemotherapy in a patient with ovarian cancer.
    Lehoczky O; Pulay T
    J Obstet Gynaecol; 2002 Nov; 22(6):694. PubMed ID: 12554276
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of chemotherapy for ovarian cancer during human pregnancy: case report and literature review.
    Mantovani G; Gramignano G; Mais V; Melis GB; Parodo G; Carrucciu GM
    Eur J Obstet Gynecol Reprod Biol; 2007 Apr; 131(2):238-9. PubMed ID: 16698170
    [No Abstract]   [Full Text] [Related]  

  • 35. Paclitaxel does not cause central nervous adverse effects: a prospective vigilance-controlled EEG mapping study in ovarian cancer patients.
    Mayerhofer K; Bodner K; Saletu B; Bodner-Adler B; Anderer P; Hefler L; Kaider A; Leodolter S; Kainz C
    Wien Klin Wochenschr; 2000 Dec; 112(23):1007-13. PubMed ID: 11190709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gynecologic oncology group trials in ovarian carcinoma.
    Ozols RF
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-10-S2-12. PubMed ID: 9045325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates.
    McGuire WP
    J Clin Oncol; 2009 Oct; 27(28):4633-4. PubMed ID: 19704055
    [No Abstract]   [Full Text] [Related]  

  • 38. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion].
    Noda K; Ikeda M; Kudo R; Nishiya I; Yajima A; Tanaka K; Kodama S; Takahashi T; Tokunaga A; Satoh I; Nozawa S; Taketani Y; Terashima Y; Isonishi S; Takeda Y; Nishijima M; Kuroshima Y; Fujii S; Izumi R; Tamaya T; Mori T; Okada H; Ogita S; Ozaki M; Hatae M
    Gan To Kagaku Ryoho; 1996 Feb; 23(3):317-25. PubMed ID: 8712825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Paclitaxel (taxol)--a cytostatic drug with a new kind of mechanism of action].
    Schalhorn B
    Med Klin Suppl; 1993 Nov; 2():4-6. PubMed ID: 7904718
    [No Abstract]   [Full Text] [Related]  

  • 40. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
    Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte PF; Genazzani AR
    Anticancer Res; 2000; 20(6C):4793-9. PubMed ID: 11205220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.